Stage IIC Melanoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB09037 | Pembrolizumab | Programmed cell death protein 1 | target |
| DB09037 | Pembrolizumab | Programmed cell death 1 ligand 1 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB17475 | Incomplete Freund's adjuvant | 0 | Completed | 1 |
| DB15081 | Melanoma antigen recognized by T-cells 1 | 0 | Completed | 1 |
| DB06530 | Resiquimod | 0 | Completed | 1 |
| DB15018 | Agatolimod | 2 | Completed | 1 |
| DB14800 | GP-100 antigen | 2 | Completed | 2 |
| DB17475 | Incomplete Freund's adjuvant | 2 | Completed | 2 |
| DB11805 | Saracatinib | 2 | Completed | 1 |
| DB00020 | Sargramostim | 2 | Completed | 1 |
| DB16626 | Tyrosinase | 2 | Completed | 2 |
| DB00020 | Sargramostim | 3 | Withdrawn | 1 |